Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models

International Journal for Parasitology

Volumn 33, Issue 7, 2003, Pages 757-764

  Mele, R ^a   Gomez Morales, M A ^a   Tosini, F ^a   Pozio, E ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral protease inhibitor; Balb c mice; Cryptosporidium parvum; Flow cytometry; Highly active antiretroviral therapy; Human ileocecal adenocarcinoma tumour cell line; Indinavir

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; ILEUM; IMMUNE DEFICIENCY; INFECTION CONTROL; INTESTINE; INTRACELLULAR SPACE; LIFE CYCLE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYST; PARASITE DEVELOPMENT; PARASITE LOCALIZATION; SPOROGENESIS; TREATMENT OUTCOME; TUMOR CELL LINE;

CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; HUMAN IMMUNODEFICIENCY VIRUS; MICROSPORIDIA;

EID: 0037840343     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(03)00093-6     Document Type: Article

References (48)

1. Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 360:2002;1375-1380.
2. Arrowood M.J., Hurd M.R., Mead J.R. A new method for evaluating experimental cryptosporidial parasite loads using immunofluorescent flow cytometry. J. Parassitol. 81:1995;404-409.
3. Atzori C., Angeli E., Mainini A., Agostoni F., Micheli V., Cargnel A. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. J. Infect. Dis. 181:2000;1629-1634.
4. Atzori C., Fantoni G., Valerio A., Cargnel A. In vitro activity of amprenavir against Pneumocystis carinii. Int. J. Antimicrob. Agents. 18:2001;271-273.
5. Bobin S., Bouhouere D., Dumpt S., Boibieux A., Grault V., Peyrnamond D. Importance of antiprotease in the treatment of microsporidia and/or cryptosporidia infections in HIV-sero positive patients. Pathol. Biol. 46:1998;418-419.
6. Cacciò S., Pinter E., Fantini R., Mezzaroma I., Pozio E. Human infection with Cryptosporidium felis: case report and literature review. Emerg. Infect. Dis. 8:2002;85-86.
7. Carr A., Marriott D., Field A., Vasak E., Cooper D.A. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet. 351:1998;2560-2561.
8. Cassone A., De Bernardis F., Torosantucci A., Tacconelli E., Tumbarello M., Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180:1999;448-453.
9. Chavan S., Kodoth S., Pahwa R., Pahwa S. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 98:2001;383-389.
10. Contamin B., Boibieux A., Gerard-Boncompain M., Bouhour D., Girault V., Biron F., Peyramond D. Cryptosporidium infection: value of a protease inhibitor. Presse Med. 26:1997;416.
11. Coombs G.H., Goldberg D.E., Klemba M., Berry C., Kay J., Mottram J.C. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17:2001;532-537.
12. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retrov. 8:1992;153-164.
13. Delaunay A., Gargala G., Li X., Favennec L., Ballet J.J. Quantitative flow cytometry evaluation of maximal Cryptosporidium parvum oocyst infectivity in a neonate mouse model. Appl. Environ. Microbiol. 66:2000;4315-4317.
14. Derouin F., Santillana-Hayat M. Anti-Toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob. Agents Chemother. 44:2000;2575-2577.
15. Fayer R., Speer C.A., Dubey J.P. General biology of Cryptosporidium. Fayer R. Cryptosporidium and Cryptosporidiosis. 1997;1-42 CRC Press, Boca Raton.
16. Fichtenbaum C.J., Ritchie D.J., Powderly W.G. Use of paromycin for treatment of cryptosporidiosis in patients with AIDS. Clin. Infect. Dis. 16:1993;298-300.
17. Forney J.R., Yang S., Du C, Healey M.C. Efficacy of serine protease inhibitors against Cryptosporidium infection in a bovine fallopian tube epithelial cell culture system. J. Parassitol. 82:1996;638-640.
18. Forney J.R., Yang S., Healey M.C. Protease activity associated with excystation of Cryptosporidium parvum oocysts. J. Parassitol. 82:1996;889-892.
19. Forney J.R., Yang S., Healey M.C. Antagonistic effect of human alpha-1-antitrypsin on excystation of Cryptosporidium parvum oocysts. J. Parassitol. 83:1997;771-774.
20. Forney J.R., De Wald D.B., Yang S., Speer C.A., Healey M.C. A role of phosphoinositide-3-kinase and cytoskeletal remodeling during C. parvum infection. Infect. Immun. 67:1999;844-852.
21. Foudraine N.A., Weverling G.J., van Gool T., Roos M.T., de Wolf F., Koopmans P.P., van den Broek P.J., Meenhorst P.L., van Leeuwen R., Lange J.M., Reiss P. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS. 12:1998;35-41.
22. Giacometti A., Burzacchini F., Cirioni O., Barchiesi F., Dini M., Scalise G. Efficacy of treatment with paromomycin, azithromycin and nitazoxanide in a patient with disseminated cryptosporidiosis. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;885-889.
23. Grube H., Ramratnam B., Ley C., Flanigan T.P. Resolution of AIDS associated cryptosporidiosis after treatment with indinavir. Am. J. Gastroenterol. 92:1997;726.
24. Gut J., Nelson R.G. Cryptosporidium parvum: syncronised excystation in vitro and evaluation of sporozoite infectivity with a new Lectin-Based Assay. J. Eukaryot. Microbiol. 46:1999;56S-57S.
25. Hamour A.A., Bonnington A., Hawthorne B., Wilkins E.G. Successful treatment of AIDS related cryptosporidial sclerosing cholangitis. AIDS. 7:1993;1449-1451.
26. Harp J.A., Sacco R.E. Development of cellular immune functions in neonatal to weanling mice: relationship to Cryptosporidium parvum infection. J. Parassitol. 82:1996;245-249.
27. Hewitt R.G., Yiannoutsos C.T., Higgs E.S., Carey J.T., Geiseler P.J., Soave R., Rosenberg R., Vazquez G.J., Wheat L.J., Fass R.J., Antoninievic Z., Walawander A.L., Flanigan T.P., Bender J.F. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis. 31:2000;1084-1092.
28. Hijjawi N.S., Meloni B.P., Morgan U.M., Thompson R.C. A Complete development and long-term maintenance of Cryptosporidium parvum human and cattle genotypes in cell culture. Int. J. Parassitol. 31:2001;1048-1055.
29. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
30. Ives N.J., Gazzard B.G., Easterbrook P.J. The changing pattern of AIDS-defining illness with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect. 42:2001;134-139.
31. Jean L., Grosclaude J., Labbe M., Tomley F., Perry P. Differential localisation of an Eimeria tenella aspartyl proteinase during the infection process. Int. J. Parasitol. 30:2000;1099-1107.
32. Laurent F., Bourdieu C., Kaga M., Chilmonczyk S., Zgrzebski G., Yvore P., Perry P. Cloning and characterisation of an Eimeria acervulina sporozoite gene homologous to aspartyl proteinases. Mol. Biochem. Parasitol. 62:1993;303-312.
33. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., Vernazza P., Sudre P., Flepp M., Furrer H., Francioli P., Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 353:1999;863-868.
34. Le Moing V., Bissuel F., Costagliola D., Eid Z., Chapuis F., Molina J.M., Salmon-Ceron D., Brasseur P., Leport C. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS. 12:1998;1395-1397.
35. Merry C., Barry M.G., Mulcahy F., Ryan M., Heavey J., Tjia J.F., Gibbons S.E., Breckenridge A.M., Back D.J. Saquinavir pharmakokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11:1997;F29-F33.
36. Miao Y.M., Awad-El-Kariem F.M., Franzen C., Ellis D.S., Muller A., Counhihan H.M., Hayes P.J., Gazzard B.G. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndrom. 25:2000;124-129.
37. Moss D.M., Arrowood M.J. Quantification of Cryptosporidium parvum oocysts in mouse fecal specimens using immunomagnetic particles and two-colour flow cytometry. J. Parasitol. 87:2001;406-412.
38. Motta I., Gissot M., Kanellopoulos J.M., Ojcius D.M. Absence of weight loss during Cryptosporidium infection in susceptible mice deficient in Fas-mediated apoptosis. Microbes Infect. 4:2002;821-827.
39. Notermans D.W., Van Lewen R., Lange J.M. Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Drug Saf. 15:1996;176-187.
40. Ranucci L., Muller H.M., La Rosa G., Reckman I., Gomez Morales M.A., Spano F., Pozio E., Crisanti A. Characterisation and immunolocalisation of a Cryptosporidium parvum protein containing repeated amino acids motifs. Inf. Immun. 61:1993;2347-2356.
41. Rossi P., Pozio E., Besse M.G., Gomez Morales M.A., La Rosa G. Experimental cryptosporidiosis in hamsters. J. Clin. Microbiol. 28:1990;356-357.
42. Rossignol J.F.A., Ayoub A., Ayers M.S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomised, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184:2001;103-106.
43. Schmidt W., Wahnschaffe U., Schäfer M., Zippel T., Arvand M., Meyerhans A., Riecken E., Ullrich R. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving Highly Active Antiretroviral Therapy. Gastroenterology. 120:2001;984-987.
44. Slifko T.R., Hoffman D.E., Rose J.B. A most probable number assay for enumeration of infectious Cryptosporidium parvum oocysts. Appl. Environ. Microbiol. 65:1999;3936-3941.
45. Tamburrini A., Pozio E. Long term survival of Cryptosporidium parvum oocysts in seawater and in experimentally infected mussels (Mytilus galloprovincialis). Int. J. Parasitol. 29:1999;711-715.
46. Upton S.J., Tilley M., Brillhart D.B. Effect of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. J. Clin. Microbiol. 33:1995;371-375.
47. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
48. Zingman B.S. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosin plus saquinavir. N. Engl. J. Med. 20:1996;1674-1675.